Haojie Jin

The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.

Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.

How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.

Assessed papers (1)

• Downregulation of Splicing Factor <i>PTBP1</i> Curtails <i>FBXO5</i> Expression to Promote Cellular Senescence in Lung Adenocarcinoma.⚑
  2024 L1 59/100 ⚑

1 assessed by us (0 reproduced) · 157 not yet assessed — every PubMed paper on record, linked below.

• Sesaminol Ameliorates Metabolic and Alcohol‐Related Liver Injury by Activating the PPARα/Slc27a5 Axis‐Driven Hepatic Fatty Acid β‐Oxidation ↗

  Molecular Nutrition & Food Research · 2026 · PMID 42170787
  not yet assessed
• Figure S5 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2026
  not yet assessed
• Figure S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2026
  not yet assessed
• Figure S8 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2026
  not yet assessed
• Figure S6 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2026
  not yet assessed
• Table S1 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2026
  not yet assessed
• Figure S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2026
  not yet assessed
• Table S4 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2026
  not yet assessed
• Table S5 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2026
  not yet assessed
• Figure S2 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2026
  not yet assessed
• Figure S10 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2026
  not yet assessed
• Table S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2026
  not yet assessed
• Figure S1 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2026
  not yet assessed
• Figure S9 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2026
  not yet assessed
• Table S2 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2026
  not yet assessed
• Table S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2026
  not yet assessed
• Table S6 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2026
  not yet assessed
• Figure S4 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2026
  not yet assessed
• Neoadjuvant therapy in primary liver cancer: From the missing piece to a new paradigm ↗

  Hepatology Communications · 2026 · PMID 42360835
  not yet assessed
• H2BE113K mutation promotes breast cancer metastasis through modulating chromatin dynamics ↗

  Science Advances · 2026 · PMID 42430466
  not yet assessed
• Hepatocellular carcinoma: signaling pathways and therapeutic advances ↗

  Signal Transduction and Targeted Therapy · 2025 · PMID 39915447
  not yet assessed
• Combination locoregional and systemic therapies in hepatocellular carcinoma ↗

  ˜The œLancet. Gastroenterology & hepatology · 2025 · PMID 39993404
  not yet assessed
• Triple knockdown of <i>CD11a</i> , <i>CD49d</i> , and <i>PSGL1</i> in T cells reduces CAR-T cell toxicity but preserves activity against solid tumors in mice ↗

  Science Translational Medicine · 2025 · PMID 39841806
  not yet assessed
• Multifunctional Bimetallic Nanoreactors for Integrative Host‐Pathogen Analysis Toward Bloodstream Infection Diagnosis ↗

  Advanced Functional Materials · 2025
  not yet assessed
• Superior elevated-temperature mechanical properties driven by TaC content in near-eutectic Re0.1Ta1.6W0.6(TaC)x composites ↗

  Journal of Alloys and Compounds · 2025
  not yet assessed
• PRMT1-mediated modification of H4R3me2a promotes liver cancer progression by enhancing the transcriptional activity of SOX18 ↗

  Hepatology Communications · 2025 · PMID 40130992
  not yet assessed
• Prognostic implications of adverse events associated with CAR-T cell therapy: a population-based global observational study ↗

  EClinicalMedicine · 2025 · PMID 41497502
  not yet assessed
• Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients ↗

  Nature Communications · 2025 · PMID 40044664
  not yet assessed
• Interpretable machine learning-derived nomogram model for early detection of persistent diarrhea in Salmonella typhimurium enteritis: a propensity score matching based case-control study ↗

  BMC Infectious Diseases · 2025 · PMID 39930383
  not yet assessed
• CRISPR screens identify the ATPase VCP as a druggable therapeutic vulnerability in cholangiocarcinoma ↗

  Proceedings of the National Academy of Sciences · 2025 · PMID 40991439
  not yet assessed
• Dual inhibition of FACT and RRM2 suppresses the progression of pancreatic ductal adenocarcinoma driven by the oncohistone H2BG53D ↗

  Cell Reports · 2025 · PMID 41284383
  not yet assessed
• Genome-wide Chromosome-specific Aneuploidy Engineering and Phenotypic Characterization with CRISPR-Taiji ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2025
  not yet assessed
• Personalized management of metabolic dysfunction-associated steatotic liver disease ↗

  iLiver · 2025 · PMID 41362693
  not yet assessed
• Living Environment and Intrinsic Capacity among Chinese Older Adults: A cross-sectional study ↗

  Research Square · 2025
  not yet assessed
• Microstructure and Tribological Behavior over a Wide Temperature Range of TiCrTaMoSi-Based Composites Fabricated via Spark Plasma Sintering ↗

  SSRN Electronic Journal · 2025
  not yet assessed
• BAY 11-7082 Ubiquitinates EGFR and Induces Apoptosis in SHH-MB via PI3K-AKT and STAT3 Pathways ↗

  Research Square · 2025
  not yet assessed
• Obesity and mortality in KDIGO stage 3 acute kidney injury: a machine learning-driven retrospective cohort study ↗

  BMC Nephrology · 2025 · PMID 41350643
  not yet assessed
• Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  Cancer Discovery · 2024 · PMID 38533987
  not yet assessed
• Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse ↗

  Cell Reports Medicine · 2024 · PMID 38508142
  not yet assessed
• Glucagon-like peptide-1 receptor agonist exendin 4 ameliorates diabetes-associated vascular calcification by regulating mitophagy through the AMPK signaling pathway ↗

  Molecular Medicine · 2024 · PMID 38720283
  not yet assessed
• Association between home and community-based services utilization and self-rated health among Chinese older adults with chronic diseases: evidence from the 2018 China Health and Retirement Longitudinal Study ↗

  BMC Public Health · 2024 · PMID 38191440
  not yet assessed
• Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial ↗

  Signal Transduction and Targeted Therapy · 2024 · PMID 39653700
  not yet assessed
• Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges ↗

  Gut · 2024 · PMID 39658264
  not yet assessed
• Downregulation of Splicing Factor PTBP1 Curtails FBXO5 Expression to Promote Cellular Senescence in Lung Adenocarcinoma⚑

  Current Issues in Molecular Biology · 2024 · PMID 39057099
  L1 59/100 ⚑
• Dynamin-related protein 1 mediates the therapeutic effect of isoliquiritigenin in diabetic intimal hyperplasia via regulation of mitochondrial fission ↗

  Hypertension Research · 2024 · PMID 38750218
  not yet assessed
• BMI status and its changes across adulthood in relation to all-cause mortality in metabolic dysfunction-associated steatotic liver disease ↗

  Journal of Hepatology · 2024 · PMID 38242323
  not yet assessed
• Data from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Interpretable machine learning-derived nomogram model for early detection of persistent diarrhea in Salmonella typhimurium enteritis: A propensity score matching based case-control study ↗

  Research Square · 2024
  not yet assessed
• A patient-centered outpatient process optimization system based on intelligent guidance: evidence from a large tertiary hospital in China. (Preprint) ↗

  2024
  not yet assessed
• Figure S9 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Table S6 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Table S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Table S1 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Table S4 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Table S4 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Table S5 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S9 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S8 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Table S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Table S2 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Table S1 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Table S2 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Table S6 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Table S5 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Table S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Table S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Data from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S4 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S10 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S2 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S2 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S8 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S6 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S6 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S5 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S4 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S1 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S10 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S1 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Figure S5 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy ↗

  2024
  not yet assessed
• Drug-drug synthetic lethality to combat liver cancer: From bench to bedside ↗

  2024
  not yet assessed
• Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy ↗

  癌症：英文版 · 2023 · PMID 37478283
  not yet assessed
• Loss of hepatic FTCD promotes lipid accumulation and hepatocarcinogenesis by upregulating PPARγ and SREBP2 ↗

  JHEP Reports · 2023 · PMID 37675273
  not yet assessed
• LCP1 knockdown in monocyte-derived macrophages: mitigating ischemic brain injury and shaping immune cell signaling and metabolism ↗

  Theranostics · 2023 · PMID 38164159
  not yet assessed
• Predicting mild cognitive impairment among Chinese older adults: a longitudinal study based on long short-term memory networks and machine learning ↗

  Frontiers in Aging Neuroscience · 2023 · PMID 37937119
  not yet assessed
• CDKN2B-AS1 mediates proliferation and migration of vascular smooth muscle cells induced by insulin ↗

  Cell and Tissue Research · 2023 · PMID 37907763
  not yet assessed
• Comprehensive analysis of prognostic value and immunotherapy prospect of brain cytoplasmic RNA1 in hepatocellular carcinoma ↗

  World Journal of Gastrointestinal Oncology · 2023 · PMID 37123057
  not yet assessed
• LICOB: a powerful organoid platform for drug discovery ↗

  Cell Research · 2023 · PMID 37730938
  not yet assessed
• Drug–drug synthetic lethality to combat cancer: From bench to bedside ↗

  Clinical and Translational Medicine · 2023 · PMID 37218919
  not yet assessed
• Preliminary investigation and application of a modified objects memory test in perioperative cognitive evaluation ↗

  Frontiers in Behavioral Neuroscience · 2023 · PMID 37035622
  not yet assessed
• COVID‐19 has causal effects on cancer risk? Something we might ignore ↗

  Journal of Medical Virology · 2023 · PMID 37587663
  not yet assessed
• Paradoxical activation of oncogenic signaling as a cancer treatment strategy ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2023
  not yet assessed
• Rational combinations of targeted cancer therapies: background, advances and challenges ↗

  Nature Reviews Drug Discovery · 2022 · PMID 36509911
  not yet assessed
• cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis ↗

  Nature Cancer · 2022 · PMID 36414711
  not yet assessed
• Functional chitosan/zein films with Rosa roxburghii Tratt leaves extracts prepared by natural deep eutectic solvents ↗

  Food Packaging and Shelf Life · 2022
  not yet assessed
• Attenuated effective connectivity of large-scale brain networks in children with autism spectrum disorders ↗

  Frontiers in Neuroscience · 2022 · PMID 36523439
  not yet assessed
• Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer ↗

  EBioMedicine · 2022 · PMID 36502574
  not yet assessed
• Local palliative therapies for unresectable malignant biliary obstruction: radiofrequency ablation combined with stent or biliary stent alone? An updated meta-analysis of nineteen trials ↗

  Surgical Endoscopy · 2022 · PMID 35296949
  not yet assessed
• The application of enhanced recovery after surgery in minimally invasive gastrectomy for gastric cancer: a meta-analysis of randomized controlled trials ↗

  Expert Review of Gastroenterology & Hepatology · 2022 · PMID 36354134
  not yet assessed
• FOXP4-AS1 May be a Potential Prognostic Biomarker in Human Cancers: A Meta−Analysis and Bioinformatics Analysis ↗

  Frontiers in Oncology · 2022 · PMID 35719909
  not yet assessed
• Comparative efficacy and safety of local palliative therapeutics for unresectable malignant biliary obstruction: a Bayesian network meta-analysis ↗

  Expert Review of Gastroenterology & Hepatology · 2022 · PMID 35639826
  not yet assessed
• Advances in the application of robotic surgical systems to gastric cancer: A narrative review ↗

  Asian Journal of Surgery · 2022 · PMID 36334999
  not yet assessed
• Clinicopathological Significance and Prognostic Values of Long Noncoding RNA BCYRN1 in Cancer Patients: A Meta-Analysis and Bioinformatics Analysis ↗

  Journal of Oncology · 2022 · PMID 35874631
  not yet assessed
• Sustained activation of EGFR-ERK1/2 signaling limits the therapeutic response to tigecycline-induced inhibition of mitochondrial translation in liver cancer ↗

  Research Square · 2022
  not yet assessed
• circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity ↗

  Nature Communications · 2021 · PMID 33436560
  not yet assessed
• EGFR activation limits the response of liver cancer to lenvatinib ↗

  Nature · 2021 · PMID 34290403
  not yet assessed
• The Cancer SENESCopedia: A delineation of cancer cell senescence ↗

  Cell Reports · 2021 · PMID 34320349
  not yet assessed
• Clinicopathological and Prognostic Significance of Long Non-coding RNA MIAT in Human Cancers: A Review and Meta-Analysis ↗

  Frontiers in Genetics · 2021 · PMID 34659354
  not yet assessed
• Acidic extracellular pH induces autophagy to promote anoikis resistance of hepatocellular carcinoma cells via downregulation of miR-3663-3p ↗

  Journal of Cancer · 2021 · PMID 33995620
  not yet assessed
• M⁶A methylation-mediated elevation of SM22α inhibits the proliferation and migration of vascular smooth muscle cells and ameliorates intimal hyperplasia in type 2 diabetes mellitus ↗

  Biological Chemistry · 2021 · PMID 34882999
  not yet assessed
• The Cancer Senescopedia – Delineation of Cancer Cell Senescence ↗

  SSRN Electronic Journal · 2021
  not yet assessed
• PPARγ Coactivator‐1α Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARγ–Dependent WNT/β‐Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis ↗

  Hepatology · 2020 · PMID 32298475
  not yet assessed
• A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer ↗

  eLife · 2020 · PMID 33016874
  not yet assessed
• COL4A1 promotes the growth and metastasis of hepatocellular carcinoma cells by activating FAK-Src signaling ↗

  Journal of Experimental & Clinical Cancer Research · 2020 · PMID 32746865
  not yet assessed
• circFOXM1 promotes proliferation of non-small cell lung carcinoma cells by acting as a ceRNA to upregulate FAM83D ↗

  Journal of Experimental & Clinical Cancer Research · 2020 · PMID 32228656
  not yet assessed
• COL4A1 promotes the growth and metastasis of hepatocellular carcinoma cells by activating FAK-Src signaling ↗

  Research Square · 2020
  not yet assessed
• Author response: A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer ↗

  2020
  not yet assessed
• COL4A1 promotes the growth and metastasis of hepatocellular carcinoma cells by activating FAK-Src signaling ↗

  Research Square · 2020
  not yet assessed
• Additional file 3 of circFOXM1 promotes proliferation of non-small cell lung carcinoma cells by acting as a ceRNA to upregulate FAM83D ↗

  Figshare · 2020
  not yet assessed
• Additional file 2 of circFOXM1 promotes proliferation of non-small cell lung carcinoma cells by acting as a ceRNA to upregulate FAM83D ↗

  Figshare · 2020
  not yet assessed
• Additional file 1 of circFOXM1 promotes proliferation of non-small cell lung carcinoma cells by acting as a ceRNA to upregulate FAM83D ↗

  Figshare · 2020
  not yet assessed
• circTP63 functions as a ceRNA to promote lung squamous cell carcinoma progression by upregulating FOXM1 ↗

  Nature Communications · 2019 · PMID 31324812
  not yet assessed
• Inducing and exploiting vulnerabilities for the treatment of liver cancer ↗

  Nature · 2019 · PMID 31578521
  not yet assessed
• A novel, liver-specific long noncoding RNA LINC01093 suppresses HCC progression by interaction with IGF2BP1 to facilitate decay of GLI1 mRNA ↗

  Cancer Letters · 2019 · PMID 30790682
  not yet assessed
• CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma ↗

  Gut · 2019 · PMID 31519701
  not yet assessed
• Self-Assembled and Self-Monitored Sorafenib/Indocyanine Green Nanodrug with Synergistic Antitumor Activity Mediated by Hyperthermia and Reactive Oxygen Species-Induced Apoptosis ↗

  ACS Applied Materials & Interfaces · 2019 · PMID 31682099
  not yet assessed
• Downregulation of PDK4 Increases Lipogenesis and Associates with Poor Prognosis in Hepatocellular Carcinoma ↗

  Journal of Cancer · 2019 · PMID 30854098
  not yet assessed
• Argininosuccinate synthase 1 suppresses cancer cell invasion by inhibiting STAT3 pathway in hepatocellular carcinoma ↗

  Acta Biochimica et Biophysica Sinica · 2019 · PMID 30883650
  not yet assessed
• Long noncoding RNA miR503HG, a prognostic indicator, inhibits tumor metastasis by regulating the HNRNPA2B1/NF-κB pathway in hepatocellular carcinoma ↗

  Theranostics · 2018 · PMID 29774077
  not yet assessed
• FUN14 Domain‐Containing 1–Mediated Mitophagy Suppresses Hepatocarcinogenesis by Inhibition of Inflammasome Activation in Mice ↗

  Hepatology · 2018 · PMID 30053328
  not yet assessed
• Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer ↗

  Journal of Hepatology · 2018 · PMID 30030148
  not yet assessed
• A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma ↗

  Cell Research · 2018 · PMID 29507396
  not yet assessed
• Hepatocyte-specific deletion of LASS2 protects against diet-induced hepatic steatosis and insulin resistance ↗

  Free Radical Biology and Medicine · 2018 · PMID 29626628
  not yet assessed
• Phospho-ERK is a response biomarker to a combination of sorafenib and MEK inhibition in liver cancer ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2018
  not yet assessed
• STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4 ↗

  Molecular Cancer · 2017 · PMID 28810927
  not yet assessed
• Synergistic Cisplatin/Doxorubicin Combination Chemotherapy for Multidrug-Resistant Cancer via Polymeric Nanogels Targeting Delivery ↗

  ACS Applied Materials & Interfaces · 2017 · PMID 28247750
  not yet assessed
• Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1 ↗

  Gastroenterology · 2017 · PMID 28583823
  not yet assessed
• Downregulation of ACSM3 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma. ↗

  PubMed · 2017 · PMID 28401010
  not yet assessed
• Application of model based system engineering to IMA development activities ↗

  2017
  not yet assessed
• Liver-specific deletion of LASS2 delayed regeneration of mouse liver after partial hepatectomy ↗

  Biochemical and Biophysical Research Communications · 2017 · PMID 28958935
  not yet assessed
• Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling ↗

  Theranostics · 2016 · PMID 27279912
  not yet assessed
• A Targetable Molecular Chaperone Hsp27 Confers Aggressiveness in Hepatocellular Carcinoma ↗

  Theranostics · 2016 · PMID 26941848
  not yet assessed
• The asialoglycoprotein receptor suppresses the metastasis of hepatocellular carcinoma via LASS2-mediated inhibition of V-ATPase activity ↗

  Cancer Letters · 2016 · PMID 27241665
  not yet assessed
• Co-expression of LASS2 and TGF-β1 predicts poor prognosis in hepatocellular carcinoma ↗

  Scientific Reports · 2016 · PMID 27581744
  not yet assessed
• Heat shock proteins in hepatocellular carcinoma: Molecular mechanism and therapeutic potential ↗

  International Journal of Cancer · 2015 · PMID 26853533
  not yet assessed
• Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration and invasion of human hepatocellular carcinoma ↗

  Scientific Reports · 2015 · PMID 26099564
  not yet assessed
• LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway ↗

  Carcinogenesis · 2015 · PMID 26249360
  not yet assessed
• Hypoxia upregulates Rab11-family interacting protein 4 through HIF-1α to promote the metastasis of hepatocellular carcinoma ↗

  Oncogene · 2015 · PMID 25745995
  not yet assessed
• LRG1 suppresses the migration and invasion of hepatocellular carcinoma cells ↗

  Medical Oncology · 2015 · PMID 25814288
  not yet assessed
• KDM6B Elicits Cell Apoptosis by Promoting Nuclear Translocation of FOXO1 in Non-Small Cell Lung Cancer ↗

  Cellular Physiology and Biochemistry · 2015 · PMID 26303949
  not yet assessed
• Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules ↗

  Oncotarget · 2015 · PMID 25749520
  not yet assessed
• Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma ↗

  Oncotarget · 2014 · PMID 25609201
  not yet assessed
• MicroRNAs in hypoxia and acidic tumor microenvironment ↗

  Chinese Science Bulletin · 2014
  not yet assessed
• Research on the effects of Zidian Shengyu Pulvis of FOXP3 in CITP

  Lishizhen Medicine and Materia Medica Research · 2014
  not yet assessed